Simple HealthKit
-33%
est. 2Y upside i
Simple HealthKit is addressing health inequity with the first human-centric, complete diagnostics platform that includes access to follow-up care for sexual wellness, respiratory health and chronic co
Rank
#2999
Sector
Digital Health / Diagnostics
Est. Liquidity
~3Y
Data Quality
Data: LowGiven uncertain valuation, significant preference overhang, and high incumbent threat, the equity upside is strongly negative in base and bear scenarios.
Last updated: July 3, 2026
IPO window opens or category leadership drives multiple expansion to 7x, yielding 102% upside net of dilution.
Exit multiple converges to public comp range of 3x, resulting in -22% upside after dilution.
Multiple compresses to 2x, with preference overhang causing common stock recovery of only 12% of entry value, net -100% after dilution.
Preference Stack Risk
severeFunding Intensity
50%Total funding of $25M represents 50% of assumed $50M entry valuation, creating a high liquidation preference overhang.
Dilution Risk
lowWith $25M funding and moderate burn, the company likely has 2-3 years of runway, so dilution risk in the next 2 years is low.
Secondary Liquidity
noneNo secondary market disclosed.
Questions to Ask at the Interview
Strategic questions based on Simple HealthKit's data — designed to show you've done your homework.
- 1
“How does Simple HealthKit differentiate its lab infrastructure from Quest and Labcorp's scale?”
- 2
“What is the company's path to profitability given the high regulatory costs?”
- 3
“How does the current equity grant structure handle dilution from future rounds?”
Community
Valuation Sentiment
Our model estimates -33% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.